<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35743993</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>58</Volume><Issue>6</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>28</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Application of Kampo Medicines for Treatment of General Fatigue Due to Long COVID.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">730</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina58060730</ELocationID><Abstract><AbstractText>Evidence regarding treatment for the acute phase of COVID-19 has been accumulating, but specific treatment for long COVID/post-COVID-19 condition has not yet been established. Treatment with herbal medicine might be one treatment option for long COVID, but there has been little research on the effectiveness of herbal medicine for long COVID. The aim of this study was to clarify the prescription patterns of Kampo medicines, which are herbal medicines that originated in China and were developed in Japan, for the treatment of general fatigue due to long COVID. A retrospective descriptive study was performed for patients who visited a COVID-19 aftercare clinic established in Okayama University Hospital during the period from Feb 2021 to Dec 2021 with a focus on symptoms accompanying general fatigue and prescriptions of Kampo medicine. Among the clinical data obtained from medical records of 195 patients, clinical data for 102 patients with general fatigue and accompanying symptoms were analyzed. The patients had various symptoms, and the most frequent symptoms accompanying general fatigue were dysosmia, dysgeusia, headache, insomnia, dyspnea, and hair loss. Prescriptions of Kampo medicine accounted for 24.1% of the total prescriptions (<i>n</i> = 609). The most frequently prescribed Kampo medicine was hochuekkito (71.6%) and other prescribed Kampo medicines were tokishakuyakusan, ryokeijutsukanto, juzentaihoto, hangekobokuto, kakkonto, ninjin'yoeito, goreisan, rikkunshito, and keishibukuryogan. Since the pathophysiology of general fatigue after an infectious disease is, in general, considered a qi deficiency in Kampo medicine, treatments with such compensation agents can be the major prescription as a complement for the qi. In conclusion, Kampo medicine can be one of the main pharmacological treatments for long COVID accompanying general fatigue.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tokumasu</LastName><ForeName>Kazuki</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ueda</LastName><ForeName>Keigo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Educational Center for Kampo Medicine, Okayama University Hospital, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Honda</LastName><ForeName>Hiroyuki</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunada</LastName><ForeName>Naruhiko</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakurada</LastName><ForeName>Yasue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuda</LastName><ForeName>Yui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakano</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9972-791X</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasegawa</LastName><ForeName>Toru</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Yuki</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-6015-6128</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Obika</LastName><ForeName>Mikako</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Educational Center for Kampo Medicine, Okayama University Hospital, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagiya</LastName><ForeName>Hideharu</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5086-1891</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kataoka</LastName><ForeName>Hitomi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Otsuka</LastName><ForeName>Fumio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7014-9095</Identifier><AffiliationInfo><Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical and Educational Center for Kampo Medicine, Okayama University Hospital, Okayama 700-8558, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005221" MajorTopicYN="N">Fatigue</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020835" MajorTopicYN="N">Medicine, Kampo</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010946" MajorTopicYN="Y">Plants, Medicinal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Kampo medicine</Keyword><Keyword MajorTopicYN="N">general fatigue</Keyword><Keyword MajorTopicYN="N">herbal medicine</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>4</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>24</Day><Hour>1</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35743993</ArticleId><ArticleId IdType="pmc">PMC9227280</ArticleId><ArticleId IdType="doi">10.3390/medicina58060730</ArticleId><ArticleId IdType="pii">medicina58060730</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nuzzo J.B., Gostin L.O. The First 2 Years of COVID-19: Lessons to Improve Preparedness for the Next Pandemic. JAMA. 2022;327:217&#x2013;218. doi: 10.1001/jama.2021.24394.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.24394</ArticleId><ArticleId IdType="pubmed">34989763</ArticleId></ArticleIdList></Reference><Reference><Citation>Carfi A., Bernabei R., Landi F., Gemelli Against C.-P.-A.C.S.G. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324:603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W., Hillman T., Playford E.D., Hishmeh L. Managing the long term effects of COVID-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., WHO Clinical Case Definition Working Group on Post-COVID-19 Condition A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 2021;22:e102&#x2013;e107. doi: 10.1016/S1473-3099(21)00703-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(21)00703-9</ArticleId><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Anaya J.M., Rojas M., Salinas M.L., Rodriguez Y., Roa G., Lozano M., Rodriguez-Jimenez M., Montoya N., Zapata E., Post-COVID Study Group et al. Post-COVID syndrome. A case series and comprehensive review. Autoimmun. Rev. 2021;20:102947. doi: 10.1016/j.autrev.2021.102947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102947</ArticleId><ArticleId IdType="pmc">PMC8428988</ArticleId><ArticleId IdType="pubmed">34509649</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazato Y., Morioka S., Tsuzuki S., Akashi M., Osanai Y., Tanaka K., Terada M., Suzuki M., Kutsuna S., Saito S., et al. Prolonged and Late-Onset Symptoms of Coronavirus Disease 2019. Open Forum Infect. Dis. 2020;7:ofaa507. doi: 10.1093/ofid/ofaa507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofaa507</ArticleId><ArticleId IdType="pmc">PMC7665672</ArticleId><ArticleId IdType="pubmed">33230486</ArticleId></ArticleIdList></Reference><Reference><Citation>Otsuka Y., Tokumasu K., Nakano Y., Honda H., Sakurada Y., Sunada N., Omura D., Hasegawa K., Hagiya H., Obika M., et al. Clinical Characteristics of Japanese Patients Who Visited a COVID-19 Aftercare Clinic for Post-Acute Sequelae of COVID-19/Long COVID. Cureus. 2021;13:e18568. doi: 10.7759/cureus.18568.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.18568</ArticleId><ArticleId IdType="pmc">PMC8571943</ArticleId><ArticleId IdType="pubmed">34760415</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurada Y., Sunada N., Honda H., Tokumasu K., Otsuka Y., Nakano Y., Hanayama Y., Furukawa M., Hagiya H., Otsuka F. Serial Changes of Long COVID Symptoms and Clinical Utility of Serum Antibody Titers for Evaluation of Long COVID. J. Clin. Med. 2022;11:1309. doi: 10.3390/jcm11051309.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11051309</ArticleId><ArticleId IdType="pmc">PMC8911256</ArticleId><ArticleId IdType="pubmed">35268400</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., Madhavan M.V., McGroder C., Stevens J.S., Cook J.R., Nordvig A.S., Shalev D., Sehrawat T.S., et al. Post-acute COVID-19 syndrome. Nat. Med. 2021;27:601&#x2013;615. doi: 10.1038/s41591-021-01283-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Raveendran A.V., Jayadevan R., Sashidharan S. Long COVID: An overview. Diabetes Metab. Syndr. 2021;15:869&#x2013;875. doi: 10.1016/j.dsx.2021.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.04.007</ArticleId><ArticleId IdType="pmc">PMC8056514</ArticleId><ArticleId IdType="pubmed">33892403</ArticleId></ArticleIdList></Reference><Reference><Citation>Simani L., Ramezani M., Darazam I.A., Sagharichi M., Aalipour M.A., Ghorbani F., Pakdaman H. Prevalence and correlates of chronic fatigue syndrome and post-traumatic stress disorder after the outbreak of the COVID-19. J. Neurovirol. 2021;27:154&#x2013;159. doi: 10.1007/s13365-021-00949-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-00949-1</ArticleId><ArticleId IdType="pmc">PMC7852482</ArticleId><ArticleId IdType="pubmed">33528827</ArticleId></ArticleIdList></Reference><Reference><Citation>Komaroff A.L., Bateman L. Will COVID-19 Lead to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome? Front. Med. 2020;7:606824. doi: 10.3389/fmed.2020.606824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.606824</ArticleId><ArticleId IdType="pmc">PMC7848220</ArticleId><ArticleId IdType="pubmed">33537329</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis S., Samudra M., Dhamija S., Chaudhury S., Saldanha D. Stigma associated with COVID-19. Ind. Psychiatry J. 2021;30:S270&#x2013;S272. doi: 10.4103/0972-6748.328827.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0972-6748.328827</ArticleId><ArticleId IdType="pmc">PMC8611585</ArticleId><ArticleId IdType="pubmed">34908707</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuda K., Straus S.E., Hickie I., Sharpe M.C., Dobbins J.G., Komaroff A. The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. Ann. Intern. Med. 1994;121:953&#x2013;959. doi: 10.7326/0003-4819-121-12-199412150-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-121-12-199412150-00009</ArticleId><ArticleId IdType="pubmed">7978722</ArticleId></ArticleIdList></Reference><Reference><Citation>Carruthers B.M., Jain A.K., De Meirleir K.L., Peterson D.L., Klimas N.G., Lerner A.M., Bested A.C., Flor-Henry P., Joshi P., Powles A.C.P., et al. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. J. Chronic Fatigue Syndr. 2003;11:7&#x2013;115. doi: 10.1300/J092v11n01_02.</Citation><ArticleIdList><ArticleId IdType="doi">10.1300/J092v11n01_02</ArticleId></ArticleIdList></Reference><Reference><Citation>Myalgic Encephalomyelitis (or Encephalopathy)/Chronic Fatigue Syndrome: Diagnosis and Management. National Institute for Health and Care Excellence: Guidelines; National Institute for Health and Care Excellence; London, UK: 2021.</Citation></Reference><Reference><Citation>White P.D., Goldsmith K.A., Johnson A.L., Potts L., Walwyn R., DeCesare J.C., Baber H.L., Burgess M., Clark L.V., Cox D.L., et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): A randomised trial. Lancet. 2011;377:823&#x2013;836. doi: 10.1016/S0140-6736(11)60096-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(11)60096-2</ArticleId><ArticleId IdType="pmc">PMC3065633</ArticleId><ArticleId IdType="pubmed">21334061</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting P., Bagnall A.M., Sowden A.J., Cornell J.E., Mulrow C.D., Ramirez G. Interventions for the treatment and management of chronic fatigue syndrome: A systematic review. JAMA. 2001;286:1360&#x2013;1368. doi: 10.1001/jama.286.11.1360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.286.11.1360</ArticleId><ArticleId IdType="pubmed">11560542</ArticleId></ArticleIdList></Reference><Reference><Citation>Afari N., Buchwald D. Chronic fatigue syndrome: A review. Am. J. Psychiatry. 2003;160:221&#x2013;236. doi: 10.1176/appi.ajp.160.2.221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.160.2.221</ArticleId><ArticleId IdType="pubmed">12562565</ArticleId></ArticleIdList></Reference><Reference><Citation>Takayama S., Namiki T., Odaguchi H., Arita R., Hisanaga A., Mitani K., Ito T. Prevention and Recovery of COVID-19 Patients With Kampo Medicine: Review of Case Reports and Ongoing Clinical Trials. Front. Pharmacol. 2021;12:656246. doi: 10.3389/fphar.2021.656246.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2021.656246</ArticleId><ArticleId IdType="pmc">PMC8261067</ArticleId><ArticleId IdType="pubmed">34248620</ArticleId></ArticleIdList></Reference><Reference><Citation>Takayama S., Kikuchi A., Makino T., Kainuma M., Namiki T., Ito T. Basic pharmacological mechanisms and clinical evidence of the efficacy of hochuekkito against infectious diseases and its potential for use against COVID-19. Tradit. Kampo Med. 2021;8:3&#x2013;21. doi: 10.1002/tkm2.1264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/tkm2.1264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato Y. Case Management of COVID-19 (Secondary Version) JMA J. 2021;4:191&#x2013;197. doi: 10.31662/jmaj.2021-0036.</Citation><ArticleIdList><ArticleId IdType="doi">10.31662/jmaj.2021-0036</ArticleId><ArticleId IdType="pmc">PMC8355701</ArticleId><ArticleId IdType="pubmed">34414312</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Terasawa K. Evidence-based Reconstruction of Kampo Medicine: Part I-Is Kampo CAM? Evid.-Based Complementary Altern. Med. eCAM. 2004;1:11&#x2013;16. doi: 10.1093/ecam/neh003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ecam/neh003</ArticleId><ArticleId IdType="pmc">PMC442105</ArticleId><ArticleId IdType="pubmed">15257321</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams D., Wu T., Yang X., Tai S., Vohra S. Traditional Chinese medicinal herbs for the treatment of idiopathic chronic fatigue and chronic fatigue syndrome. Cochrane Database Syst. Rev. 2009:CD006348. doi: 10.1002/14651858.CD006348.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD006348.pub2</ArticleId><ArticleId IdType="pubmed">19821361</ArticleId></ArticleIdList></Reference><Reference><Citation>Traditional Chinese Medicine&#x2014;Controlled Vocabulary Index on Japanese Kampo Formulas and Indication Codes for Products. International Organization for Standardization; Geneva, Switzerland: 2018.</Citation></Reference><Reference><Citation>Chen R., Moriya J., Yamakawa J., Takahashi T., Li Q., Morimoto S., Iwai K., Sumino H., Yamaguchi N., Kanda T. Brain atrophy in a murine model of chronic fatigue syndrome and beneficial effect of Hochu-ekki-to (TJ-41) Neurochem. Res. 2008;33:1759&#x2013;1767. doi: 10.1007/s11064-008-9620-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-008-9620-1</ArticleId><ArticleId IdType="pubmed">18317925</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R., Moriya J., Luo X., Yamakawa J., Takahashi T., Sasaki K., Yoshizaki F. Hochu-ekki-to combined with interferon-gamma moderately enhances daily activity of chronic fatigue syndrome mice by increasing NK cell activity, but not neuroprotection. Immunopharmacol. Immunotoxicol. 2009;31:238&#x2013;245. doi: 10.1080/08923970802391525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08923970802391525</ArticleId><ArticleId IdType="pubmed">18791913</ArticleId></ArticleIdList></Reference><Reference><Citation>Song Q.H., Toriizuka K., Jin G.B., Yabe T., Cyong J.C. Long term effects of Toki-shakuyaku-san on brain dopamine and nerve growth factor in olfactory-bulb-lesioned mice. Jpn. J. Pharmacol. 2001;86:183&#x2013;188. doi: 10.1254/jjp.86.183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1254/jjp.86.183</ArticleId><ArticleId IdType="pubmed">11459120</ArticleId></ArticleIdList></Reference><Reference><Citation>Sat&#x14d; Y. Introduction to Kampo: Japanese Traditional Medicine. Elsevier; Tokyo, Japan: 2005. The Japan Society for Oriental Medicine. Diagnosis and treatment.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>